C. difficile

The investigational therapy RBX2660 has demonstrated positive trends in efficacy and safety for reducing recurrent Clostridioides difficile (C. difficile) infection over 6 months, in a recent study.

Approximately 450,000 cases of Clostridioides difficile infection occur each year in the United States and approximately 25% of patients treated for an initial episode will experience recurrence.

Further, while there is ambiguity surrounding the treatment of IBD flare in patients with CDI, case reports suggest corticosteroid initiation after appropriate antibiotic therapy may be effective.

The antibiotic fights both resistant enterococcus, streptococcus, and staphylococcus bacteria via a unique mechanism of action, which causes resistance to develop at a very slow pace.

Fecal microbiota transplants are effective in at least 80% of C. diff cases, although until now, researchers did not know why.

The overuse of antibiotics in hospitals can lead to the emergence of drug-resistant strains of bacteria or outbreaks of infections by bacteria, such as Clostridiodes difficile (C. difficile).

Through investigating a type of toxin released by the most dangerous strains of C. diff, researchers now have a map for developing drugs that can block the toxin and prevent the bacteria from entering human cells.

The findings reveal a unique mechanism for C.diff survival in the human gut and suggest novel strategies for weakening its defenses, according to the study authors.

Although clostridioides difficile is the leading cause of health care-associated infection in the United States, there are currently only 2 antibiotics available for its treatment: vancomycin and fidaxomicin.

Findings show that an inflamed environment allows clostridioides difficile to thrive in an environment that is inhospitable to competing bacteria.

Fecal microbiota transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C diff) infections, according to a study by the University of Birmingham.

The change in guidelines address how to assess damage to the kidneys caused by fluid loss associated with severe C. diff infection.

A commonly used drug made from secondary bile acids can affect the life cycle of Clostridioides difficile.

Fidaxomicin is a macrolide antibacterial medicine indicated to be used to treat infections that are proven or strongly suspected to be caused by C. difficile.

The easiest way to avoid misdiagnosis, inappropriate treatment, and potential loss of reimbursement is to prevent unsuitable testing.

A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.

Hospital-onset C. difficile infection decreased after implementing daily cleaning, health care worker hand hygiene, patient hand hygiene, screening at admission, and patient transfer reduction.

Vancomycin hydrochloride may reduce the burden on pharmacists treating patients with Clostridium Difficile.

The study found patients who were prescribed antibiotics for dental procedures tended to be older and more likely to receive clindamycin, an antibiotic that is associated with C diff infection.

Sharp Spike Underscores Need for New Treatments

Clostridium difficile (C. difficile) infections could be a cause of travel-associated diarrhea.

Hospitalized patients with Clostridium difficile (C. difficile) infection are at an increased risk of colonization if they are considered frail.

A majority of the children with C. difficile were prescribed at least 1 antibiotic in the 12 weeks leading up to their diagnosis.

A recently-published study in JAMA suggests that Clostridium difficile may be more effectively treated with vancomycin than its more commonly used counterpart metronidazole.

Using bezlotoxumab lowers the rate of recurrent Clostridium difficile infection more than a placebo alone, according to results of 2 phase 3 trials published this week in the New England Journal of Medicine.

Roche's new tests to detect Clostridium difficile and genital herpes infection have been cleared by the FDA.

Clostridium difficile-associated diarrhea (CDAD) is an increasingly common cause of inpatient mortality, and recurrent CDAD remains clinically challenging.

The US Centers for Disease Control and Prevention today reported that nearly half a million Clostridium difficile infections occurred in a single year, highlighting a critical need for improved antibiotic use.